drugset / Trial / NCT00992342

A Phase 1 Study To Evaluate The Safety And Tolerability Of Different Doses Of PF-03893787 In Healthy Adult Volunteers

NCT00992342

Phase 1 Completed 36 enrolled Pfizer
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to investigate safety and toleration of multiple oral doses as well as the time course of PF-03893787 concentration in the blood following dosing by oral solution.

Timeline

Start
2009-11
Primary completion
2010-03
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ADRIFORANT Small molecule 5 mg Oral
Subject ADRIFORANT Small molecule 15 mg Oral
Subject ADRIFORANT Small molecule 50 mg Oral

Indications

No indication recorded.